• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients

Tronvik, Erling; Stovner, Lars Jacob; Bovim, Gunnar; White, Linda; Gladwind, AJ; Owen, k; Schrader, Harald
Journal article, Peer reviewed
Thumbnail
View/Open
1471-2377-8-4.pdf (189.7Kb)
URI
http://hdl.handle.net/11250/2353224
Date
2008
Metadata
Show full item record
Collections
  • Institutt for nevromedisin og bevegelsesvitenskap [1709]
  • Publikasjoner fra CRIStin - NTNU [20842]
Original version
BMC Neurology 2008, 26(8)   10.1186/1471-2377-8-4
Abstract
Background: The main objective of this study was to investigate the angiotensin converting

enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura)

compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor,

lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to

ACE genotype.

Methods: 347 migraine patients aged 18–68 (155 migraine without aura (MoA), 187 migraine with

aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years

of age were included in the study. A polymerase chain reaction (PCR) was performed on the

genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms.

Results: No significant differences between migraine patients and controls were found with regard

to ACE genotype and allele distributions. Furthermore, there was no significant difference between

the controls and the MwA or MoA subgroups.

Conclusion: In our sample there is no association between ACE genotype or allele frequency and

migraine. In addition, ACE genotype in our experience did not predict the clinical response to

lisinopril or candesartan used as migraine prophylactics.
Publisher
BioMed Central
Journal
BMC Neurology

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit